Keyword: Indivior

Indivior is debuting its first TV campaign for opioid addiction drug Sublocade, with normality in recovery as its central theme.

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

After shelling out $1.4 billion to wrap up a federal marketing probe, Reckitt Benckiser is now ponying up another $700 million in a six-state deal.

With the feds sniffing around Indivior’s marketing of Suboxone film, the drugmaker’s former parent company is clearing its name for $1.4 billion.

Indivior cut its 2019 sales projections nearly in half after a $3 billion indictment accused the company of illegally marketing Suboxone Film.

Indivior made billions from fraudulent marketing of its opioid dependence drugs, the feds allege in a new indictment.

Takeda pulls an FDA filing for Ninlaro and is ordered to pay $155 million in a Shire patent case; a cancer startup gets Chinese investors' attention.

Indivior has been fighting off generics to top-selling Suboxone, but an appeals court has unleashed copycats now charging toward launches next week.